Ajanta Pharma is a specialty pharmaceutical company engaged in development, manufacturing and marketing of quality finished dosages. Its business includes Branded Generics in emerging markets of Asia and Africa, Generics in the developed markets of USA and Institution sales.
    The branded generics business is spread in India and more than 30 emerging countries across Africa, South East Asia, West Asia, and CIS. In India it has presence in high growth specialty segments of cardiology, dermatology, ophthalmology and pain management.
    Emerging markets are the major contributors in its branded generic business where it is present across Asia and Africa.

    It is gradually building a meaningful presence in the US market with select product portfolio, which include complex technology products to get the competitive advantage in the market place. It expects US market to be its key growth driver in the coming years.

    Company’s Institutional business comprises of supplies to various government bodies in India and supply of Anti-Malarial products under WHO approved programs in Africa.
    Ajanta Pharma employs around 7,000 people worldwide. The company operates 7 manufacturing facilities in India, 2 of which have been successfully approved by the US FDA. The company’s R&D center has a team of over 750 scientists.
    For more information about the company, click http://www.ajantapharma.com/

    Objects of the Buyback
    i) Distribute surplus funds to shareholders and thereby enhance their overall return.
    ii) Improve financial ratios like Earnings per share , Return on assets and Return on Equity

    Ajanta Pharma Buyback Details
    Issue Period Feb 3, 2022 – Feb 16, 2022
    Security Name Ajanta Pharma Limited
    Issue Type Tender Offer
    Issue Size (Shares) 0.11 Crores
    Issue Size (Amount) Rs 285.60 Crores
    Buyback Price Rs 2550 per share
    Face Value Rs 2 per share
    Listing At BSE, NSE

    Ajanta Pharma Buyback Issue Timetable
    Offer Opens On Feb 3, 2022
    Offer Closes On Feb 16, 2022
    Record Date Jan 14, 2022
    Last Date for receipt of Tender Forms Feb 16, 2022
    Finalisation of Buyback Acceptance Feb 24, 2022
    Last Date for settlment of bids Feb 25, 2022
    Last Date for Extinguishment of Shares Mar 4, 2022

    Buyback Ratio

    Category : Reserved Category for Small Shareholders
    30 Equity Shares out of every 151 shares held on the record date.
    Category : General .. for all other Eligible Shareholders
    1 Equity Shares out of every 91 shares held on the record date.

    Registered office of Ajanta Pharma Limited
    ‘Ajanta House’, 98 Govt Industrial Area, Chark
    Kandivli (West),
    Mumbai – 400 067, India

    Ajanta Pharma Lead Manager(s)
    Vivro Financial Services Private Limited
    Registered Broker
    Pravin Ratilal Share and Stock Brokers Limited

    Ajanta Pharma Buyback Registrar
    Link Intime India Private Ltd

    Chanakya’s Observations:

    Leave a Reply

    Your email address will not be published. Required fields are marked *